Cargando…

Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients

Acute graft-versus-host disease (aGvHD) is the most common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and significantly linked with morbidity and mortality. Although much work has been engaged to investigate aGvHD pathogenesis, the understanding of alloreactive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Zengkai, Huang, Aijie, He, Yang, Zhang, Zilu, Jiang, Chuanhe, Wang, Luxiang, Qing, Kai, Zhang, Sujiang, Wang, Jianmin, Hu, Xiaoxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989838/ https://www.ncbi.nlm.nih.gov/pubmed/35401560 http://dx.doi.org/10.3389/fimmu.2022.850177

Ejemplares similares

Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation
por: Lv, Meng, et al.
Publicado: (2013)

Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders
por: Biagi, Elena, et al.
Publicado: (2019)

Longitudinal proteomics study of serum changes after allogeneic HSCT reveals potential markers of metabolic complications related to aGvHD
por: Wong, Sing Ying, et al.
Publicado: (2022)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

An Intelligent Clinical Decision Support System for Predicting Acute Graft-versus-host Disease (aGvHD) following Allogeneic Hematopoietic Stem Cell Transplantation
por: Salehnasab, Cirruse, et al.
Publicado: (2021)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Antibody- and aptamer-strategies for GvHD prevention
por: Oelkrug, Christopher, et al.
Publicado: (2015)

Established and Emerging Treatments of Skin GvHD
por: Link-Rachner, Cornelia S., et al.
Publicado: (2022)

Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
por: Buxbaum, Nataliya P., et al.
Publicado: (2022)

The crosstalk between MYC and mTORC1 during osteoclastogenesis
por: Bae, Seyeon, et al.
Publicado: (2022)

The Role of Bacteria and Pattern Recognition Receptors in GvHD
por: Holler, E., et al.
Publicado: (2010)

De novo myelodysplastic syndrome in a Rothmund-Thomson Syndrome patient with novel pathogenic RECQL4 variants
por: Jiang, Chuanhe, et al.
Publicado: (2023)

Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function
por: Imanishi, Takayuki, et al.
Publicado: (2019)

Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients
por: Huang, Jiayu, et al.
Publicado: (2023)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

New insights about immune populations in gastrointestinal GvHD
por: Hayase, Eiko, et al.
Publicado: (2023)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

Effects of immune system cells in GvHD and corresponding therapeutic strategies
por: Tavaf, Maryam Jadid, et al.
Publicado: (2023)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

CrkL is required for donor T cell migration to GvHD target organs
por: Roy, Nathan H., et al.
Publicado: (2020)

Accumulation of T-cell-suppressive PD-L1(high) extracellular vesicles is associated with GvHD and might impact GvL efficacy
por: Baur, Rebecca, et al.
Publicado: (2023)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

Antigen-Specific Priming is Dispensable in Depletion of Apoptosis-Sensitive T Cells for GvHD Prophylaxis
por: Yarkoni, Shai, et al.
Publicado: (2014)

Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells
por: Riegel, Christin, et al.
Publicado: (2019)

Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
por: Roberto, Crocchiolo, et al.
Publicado: (2021)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
por: Bojanic, Ines, et al.
Publicado: (2023)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
por: Crocchiolo, Roberto, et al.
Publicado: (2021)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
por: Monzavi, Seyed Mostafa, et al.
Publicado: (2022)

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
por: Li, Yan-Ruide, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3c51gtf6tpmg050oe00kici7g